NCT05320757View on ClinicalTrials.gov

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Endometrial Cancer

Interventions

DRUG

Olaparib

a PARP inhibitor

Trial Locations (1)

Unknown

The University of Hong Kong, Hong Kong

All Listed Sponsors

lead

The University of Hong Kong

OTHER